- | Country : -
- | organs : -
- | Specialty : -
Extract
The primary objective of this study is to compare the objective response rate of enzastaurin given in combination with docetaxel and prednisone followed by enzastaurin maintenance therapy in patients with HRPC during first-line therapy versus placebo plus docetaxel and prednisone followed by placebo as maintenance. An objective response rate is assessed via objective lesion response and a 50% decline from baseline in PSA.
Inclusion criteria
- Androgen-independent metastatic prostate cancer